ADMA Biologics Inc $ADMA Shares Sold by Summit Global Investments

Summit Global Investments lowered its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 67.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 20,454 shares of the biotechnology company’s stock after selling 43,360 shares during the period. Summit Global Investments’ holdings in ADMA Biologics were worth $372,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ADMA. Skandinaviska Enskilda Banken AB publ acquired a new position in ADMA Biologics in the first quarter worth about $35,000. SVB Wealth LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at about $35,000. Cullen Frost Bankers Inc. boosted its holdings in shares of ADMA Biologics by 112.5% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,081 shares during the period. Toth Financial Advisory Corp grew its position in shares of ADMA Biologics by 1,081.6% during the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 2,293 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics during the second quarter worth about $46,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Trading Up 4.9%

NASDAQ:ADMA opened at $19.21 on Wednesday. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of 22.34 and a beta of 0.40. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The business has a fifty day moving average of $15.37 and a 200-day moving average of $17.28.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 EPS. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.